Segment Information (Tables)

9 Months Ended

12 Months Ended

Jan. 31, 2015

Apr. 30, 2014

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following tables summarize, for the periods indicated, operating results by reportable segment (in thousands):

	Personalized		Translational
	Oncology		Oncology		Unallocated
	Solutions		Solutions		Corporate
Three Months Ended January 31, 2015	(POS)		(TOS)		Overhead		Consolidated
Net revenue	$	453	$	1,376	$	-	$	1,829
Direct cost of services		(672)		(1,300)		-		(1,972)
Sales and marketing costs		(366)		(613)		-		(979)
Other operating expenses		-		(1,028)		(612)		(1,640)
Stock- based compensation expense (1)		-		-		(657)		(657)
Segment profit (loss)	$	(585)	$	(1,565)	$	(1,269)	$	(3,419)

	Personalized		Translational
	Oncology		Oncology		Unallocated
	Solutions		Solutions		Corporate
Three Months Ended January 31, 2014	(POS)		(TOS)		Overhead		Consolidated
Net revenue	$	590	$	3,100	$	-	$	3,690
Direct cost of services		(608)		(1,007)		-		(1,615)
Sales and marketing costs		(405)		(352)		-		(757)
Other operating expenses		-		(531)		(1,254)		(1,785)
Stock- based compensation expense (1)		-		-		(941)		(941)
Segment profit (loss)	$	(423)	$	1,210	$	(2,195)	$	(1,408)

	Personalized		Translational
	Oncology		Oncology		Unallocated
	Solutions		Solutions		Corporate
Nine Months Ended January 31, 2015	(POS)		(TOS)		Overhead		Consolidated
Net revenue	$	1,245	$	4,377	$	-	$	5,622
Direct cost of services		(2,171)		(3,205)		-		(5,376)
Sales and marketing costs		(1,243)		(1,650)		-		(2,893)
Other operating expenses		-		(3,490)		(2,413)		(5,903)
Stock- based compensation expense (1)		-		-		(2,284)		(2,284)
Segment profit (loss)	$	(2,169)	$	(3,968)	$	(4,697)	$	(10,834)

	Personalized		Translational
	Oncology		Oncology		Unallocated
	Solutions		Solutions		Corporate
Nine Months Ended January 31, 2014	(POS)		(TOS)		Overhead		Consolidated
Net revenue	$	1,834	$	7,258	$	-	$	9,092
Direct cost of services		(2,078)		(2,572)		-		(4,650)
Sales and marketing costs		(1,159)		(812)		-		(1,971)
Other operating expenses		-		(1,595)		(2,790)		(4,385)
Stock- based compensation expense (1)		-		-		(1,968)		(1,968)
Segment profit (loss)	$	(1,403)	$	2,279	$	(4,758)	$	(3,882)

(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

Year Ended April 30, 2014	Personalized Oncology Solutions (POS)		Translational Oncology Solutions (TOS)		Unallocated Corporate Overhead		Consolidated
Net revenue	$	2,264	$	9,286	$	-	$	11,550
Direct cost of services		(2,667)		(3,496)		-		(6,163)
Sales and marketing costs		(1,723)		(1,080)		-		(2,803)
Other operating expenses		-		(2,209)		(3,828)		(6,037)
Stock compensation expense (1)		-		-		(2,807)		(2,807)
Segment profit (loss)	$	(2,126)	$	2,501	$	(6,635)	$	(6,260)

Year Ended April 30, 2013	Personalized Oncology Solutions (POS)		Translational Oncology Solutions (TOS)		Unallocated Corporate Overhead		Consolidated
Net revenue	$	2,390	$	5,933	$	-	$	8,323
Direct cost of services		(2,604)		(2,637)		-		(5,241)
Sales and marketing costs		(1,496)		(938)		-		(2,434)
Other operating expenses		(134)		(1,753)		(2,606)		(4,493)
Stock compensation expense (1)		-		-		(2,376)		(2,376)
Segment loss	$	(1,844)	$	605	$	(4,982)	$	(6,221)

(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.